Page last updated: 2024-11-12

imidocarb dipropionate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID9983292
CHEMBL ID1362780
SCHEMBL ID2885201
MeSH IDM0099455

Synonyms (51)

Synonym
55750-06-6
AC-20135
imidocarb dipropionate
n,n'-bis(3-(4,5-dihydro-1h-imidazol-2-yl)phenyl)urea dipropionate
NCGC00166399-01
einecs 259-791-8
1,3-bis[3-(4,5-dihydro-1h-imidazol-2-yl)phenyl]urea; propanoic acid
cas-55750-06-6
tox21_112415
dtxsid4046604 ,
dtxcid2026604
A830788
zsm1m03shc ,
unii-zsm1m03shc
FT-0630686
AKOS015888295
S5214
SCHEMBL2885201
NCGC00174046-02
tox21_112415_1
3,3'-di-2-imidazolin-2-ylcarbanilide dipropionate
imidocarb dipropionate [mart.]
imidocarb dipropionate [green book]
CHEMBL1362780
Q-201233
imidocarb dipropionate, antibiotic for culture media use only
n,n'-bis(3-(4,5-dihydro-1h-imidazol-2-yl)-phenyl)
I0957
EX-A981
imidocarb dipropionate, vetranal(tm), analytical standard
F17388
1,3-bis(3-(4,5-dihydro-1h-imidazol-2-yl)phenyl)urea dipropionate
2-yl)phenyl)urea dipropionate
1,3-bis(3-(4,5-dihydro-1h-imidazol-
mfcd00013161
imidocarb (dipropionate)
HY-107496
AS-17387
BCP12142
n,n'-bis[3-(4,5-dihydro-1h-imidazol-2-yl)phenyl]urea, dipropanoate
imidocarb propionate
CCG-269667
CS-0028632
Q27295871
imidocarb 100 microg/ml in methanol
EN300-19626019
1,3-bis[3-(4,5-dihydro-1h-imidazol-2-yl)phenyl]urea; bis(propanoic acid)
imidocarb dipropionate 1000 microg/ml in acetonitrile
SY066666
imidocarb dipropionate (mart.)
imizol equine injection

Research Excerpts

Overview

Imidocarb dipropionate (IMD) is an immunomodulator agent commonly used for treatment of anaplasmosis in cattle.

ExcerptReferenceRelevance
"Imidocarb dipropionate (IMD) is an immunomodulator agent commonly used for treatment of anaplasmosis in cattle."( Validated Stability Indicating Chromatographic Methods for Quantification of Imidocarb Dipropionate; Application for the Determination of Its Residues in Bovine Meat and Milk Samples.
Morsy, F; Naguib, DM; Sedik, GA; Zaazaa, HE, 2020
)
2.23

Toxicity

Imidocarb dipropionate use in the control group was associated with serious adverse effects including signs of abdominal pain (4/7 horses) and diarrhea (2/7). A combination of butylscopolammonium bromide and metamizole sodium may be useful to ameliorate the adverse effects.

ExcerptReferenceRelevance
" Studies on the toxicology, residues and metabolism of IMDP showed this to be a safe dosage regimen."( Efficacy, toxicity and metabolism of imidocarb dipropionate in the treatment of Babesia ovis infection in sheep.
Clampitt, RB; Crawley, RJ; James, JA; McHardy, N; Woollon, RM, 1986
)
0.54
" The adverse effects of imidocarb may be due to excessive acetylcholine action."( Adverse effects of imidocarb dipropionate (Imizol) in a dog.
Abdullah, AS; Baggot, JD; Sheikh-Omar, AR; Zamri, M, 1984
)
0.6
" Atropine and glycopyrrolate are anticholinergics that could reduce the adverse effects of imidocarb."( Comparison of glycopyrrolate and atropine in ameliorating the adverse effects of imidocarb dipropionate in horses.
Donnellan, CM; Guthrie, AJ; Nurton, JP; Page, PC; van den Berg, JS, 2013
)
0.62
"To compare glycopyrrolate and atropine in ameliorating the adverse effects of imidocarb dipropionate in horses and to determine the effect of combinations of these drugs on the gastrointestinal tract."( Comparison of glycopyrrolate and atropine in ameliorating the adverse effects of imidocarb dipropionate in horses.
Donnellan, CM; Guthrie, AJ; Nurton, JP; Page, PC; van den Berg, JS, 2013
)
0.84
"Results of this study suggest that glycopyrrolate is superior to atropine in ameliorating the adverse effects of imidocarb."( Comparison of glycopyrrolate and atropine in ameliorating the adverse effects of imidocarb dipropionate in horses.
Donnellan, CM; Guthrie, AJ; Nurton, JP; Page, PC; van den Berg, JS, 2013
)
0.62
"Glycopyrrolate could be administered with imidocarb in horses with piroplasmosis to reduce the adverse effects of imidocarb."( Comparison of glycopyrrolate and atropine in ameliorating the adverse effects of imidocarb dipropionate in horses.
Donnellan, CM; Guthrie, AJ; Nurton, JP; Page, PC; van den Berg, JS, 2013
)
0.62
"To evaluate the ability of atropine sulfate, butylscopolammonium bromide combined with metamizole sodium, and flunixin meglumine to ameliorate the clinical adverse effects of imidocarb dipropionate in horses."( Evaluation of the use of atropine sulfate, a combination of butylscopolammonium bromide and metamizole sodium, and flunixin meglumine to ameliorate clinical adverse effects of imidocarb dipropionate in horses.
Abutarbush, SM; Al-Majali, AM; Alfaqeeh, SM; Mustafa, G; Qura'n, L, 2013
)
0.78
"Imidocarb dipropionate use in the control group was associated with serious adverse effects including signs of abdominal pain (4/7 horses) and diarrhea (2/7)."( Evaluation of the use of atropine sulfate, a combination of butylscopolammonium bromide and metamizole sodium, and flunixin meglumine to ameliorate clinical adverse effects of imidocarb dipropionate in horses.
Abutarbush, SM; Al-Majali, AM; Alfaqeeh, SM; Mustafa, G; Qura'n, L, 2013
)
2.03
"A combination of butylscopolammonium bromide and metamizole sodium may be useful to ameliorate the adverse effects of imidocarb dipropionate in horses, although group size was small and significant differences from the control group were not found."( Evaluation of the use of atropine sulfate, a combination of butylscopolammonium bromide and metamizole sodium, and flunixin meglumine to ameliorate clinical adverse effects of imidocarb dipropionate in horses.
Abutarbush, SM; Al-Majali, AM; Alfaqeeh, SM; Mustafa, G; Qura'n, L, 2013
)
0.79
" All three treatments showed good tolerance and safety with scarce adverse events observed."( Efficacy, safety and tolerance of imidocarb dipropionate versus atovaquone or buparvaquone plus azithromycin used to treat sick dogs naturally infected with the Babesia microti-like piroplasm.
Bartolomé, A; Checa, R; Gálvez, R; González-Fraga, JL; Marino, V; Miró, G; Montoya, A; Ortega, N, 2017
)
0.73

Pharmacokinetics

ExcerptReferenceRelevance
" The elimination rate constant and, in turn, the half-life were not altered by the endotoxin-induced fever in either species."( Influence of Escherichia coli endotoxin-induced fever on pharmacokinetics of imidocarb in dogs and goats.
Abdullah, AS; Baggot, JD, 1984
)
0.27
"The pharmacokinetic behaviour of gentamicin sulphate (3."( Effect of sodium methyl arsinate and imidocarb dipropionate antiprotozoal drugs on the pharmacokinetic of gentamicin in equines.
Soliman, GA, 1998
)
0.57
" Despite the differences in pharmacokinetic behavior, and considering the sensitivity of pathogens to imidocarb, the same dosage regimen can be used for clinical efficacy against Babesia spp."( Pharmacokinetics and mammary elimination of imidocarb in sheep and goats.
Belloli, C; Crescenzo, G; Lai, OR; Ormas, P; Sasso, G; Zizzadoro, C, 2006
)
0.33
"h and a mean half-life of 13."( Pharmacokinetics and bioavailability of imidocarb dipropionate in swine.
Li, XB; Su, D; Wang, L; Wang, ZJ; Wu, WX; Xu, JQ, 2007
)
0.61

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" Studies on the toxicology, residues and metabolism of IMDP showed this to be a safe dosage regimen."( Efficacy, toxicity and metabolism of imidocarb dipropionate in the treatment of Babesia ovis infection in sheep.
Clampitt, RB; Crawley, RJ; James, JA; McHardy, N; Woollon, RM, 1986
)
0.54
" Despite the differences in pharmacokinetic behavior, and considering the sensitivity of pathogens to imidocarb, the same dosage regimen can be used for clinical efficacy against Babesia spp."( Pharmacokinetics and mammary elimination of imidocarb in sheep and goats.
Belloli, C; Crescenzo, G; Lai, OR; Ormas, P; Sasso, G; Zizzadoro, C, 2006
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
acetylcholinesteraseHomo sapiens (human)Potency5.53550.002541.796015,848.9004AID1347395; AID1347397; AID1347398
TDP1 proteinHomo sapiens (human)Potency11.23930.000811.382244.6684AID686978; AID686979
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency0.50350.001022.650876.6163AID1224838; AID1224893
farnesoid X nuclear receptorHomo sapiens (human)Potency10.31960.375827.485161.6524AID743217
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency26.60320.000323.4451159.6830AID743065
DNA polymerase kappa isoform 1Homo sapiens (human)Potency7.51930.031622.3146100.0000AID588579
lamin isoform A-delta10Homo sapiens (human)Potency0.00180.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (34)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (97)

TimeframeStudies, This Drug (%)All Drugs %
pre-199015 (15.46)18.7374
1990's11 (11.34)18.2507
2000's26 (26.80)29.6817
2010's33 (34.02)24.3611
2020's12 (12.37)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 55.62

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index55.62 (24.57)
Research Supply Index4.72 (2.92)
Research Growth Index4.77 (4.65)
Search Engine Demand Index90.03 (26.88)
Search Engine Supply Index2.02 (0.95)

This Compound (55.62)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials11 (11.00%)5.53%
Reviews2 (2.00%)6.00%
Case Studies19 (19.00%)4.05%
Observational0 (0.00%)0.25%
Other68 (68.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]